Bristol-Myers, Vedanta Set Cancer Collaboration
December 10 2018 - 7:41AM
Dow Jones News
By Colin Kellaher
Bristol-Myers Squibb Co. (BMY) and Vedanta Biosciences on Monday
said they will evaluate Bristol-Myers' cancer drug Opdivo in
combination with Vedanta's VE800 microbiome-based immuno-oncology
candidate in patients with advanced or metastatic cancers.
Bristol-Myers said it will make an equity investment in Vedanta,
an affiliate of Boston biopharmacy company PureTech Health PLC
(PRTC.LN), which owned 71.5% of Vedanta as of June 30. Terms of the
investment weren't disclosed.
"Our collaboration with Vedanta Biosciences will allow us to
gain a deeper understanding about the emerging microbiome
landscape, its role in oncology, and the potential to improve
outcomes for patients with advanced or metastatic cancer," the New
York drug maker said.
The companies said Vedanta will maintain control of its VE800
program, including global research and development and commercial
rights.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2018 08:26 ET (13:26 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024